Quantib AI Node is designed for more rapid processing of CT and MRI scans.
Artificial intelligence (AI) solutions company Quantib secured 510(k) clearance from the U.S. Food & Drug Administration (FDA) this week for its AI workflow integration platform, Quantib AI Node.
Designed to help radiologists process CT and MRI scans faster, company officials said, the “plug-and-play” tool can assist with more rapid diagnosis, potentially leading to better outcomes.
“Quick, accurate diagnoses are the first crucial step towards better outcomes, yet most of the platforms radiologist are told to work with remain underutilized because of a complicated user experience,” said Arthur Post Uiterweer, Quantib’s chief executive officer.
Company leaders said they hope securing FDA clearance will enable the platform to alleviate some pressures caused by resources that are already stretched thin due to the COVID-19 pandemic. To bring its solution closer to radiologists state-side, the Netherlands-based company has opened a New-York based office.
So far, said one investigator who has tested Quantib’s AI platform, the tool’s performance has been effective.
“Our (pre-clinical) experience with the new Quantib AI Node is excellent,” said Wouter Veldhuis, M.D., Ph.D., a radiologist with the University Medical Center Utrecht. “It integrates seamlessly and already shows it can scale with increasing load and newly available algortihms. I really see this helping us improve patient care.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.